Clinical Trial Update: A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) [Phase 1]

View source ↗

Summary

Phase 1 study of ARC-521 in healthy adult volunteers and patients with chronic hepatitis B was terminated; results were posted on 2018-09-25.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-521

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Hepatitis B | Phase 1 | Status: TERMINATED | Results posted: 2018-09-25